Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear ER α activation
The genito-urinary syndrome of menopause has a negative impact on quality of life of postmenopausal women. The treatment of vulvo-vaginal atrophy (VVA) includes administration of estrogens. However, oral estrogen treatment is controversial due to its potential risks on venous thrombosis and breast cancer. Estetrol (E4) is a natural estrogen synthesized exclusively during pregnancy by the human fetal liver and initially considered as a weak estrogen. However, E4 was recently evaluated in a phase I-II clinical studies and found to act as an oral contraceptive in combination with a progestin, without increasing the level of coagulation factors.
Source: American Journal of Pathology - Category: Pathology Authors: Thibaut Benoit, Marie-Cecile Valera, Coralie Fontaine, Melissa Buscato, Francoise Lenfant, Isabelle Raymond-Letron, Florence Tremollieres, Michel Soulie, Jean-Michel Foidart, Xavier Game, Jean-Francois Arnal Tags: Regular Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Liver | Men | Menopause | Oral Cancer | Pathology | Pregnancy | Pregnancy and Breast Cancer | Study | Thrombosis | Urology & Nephrology | Women